aim to identify the faecal fungal secretome in patients with CRC-stricken gut.

Methods Faecal samples from 26 clinically-diagnosed patients with CRC and 20 non-CRC control individuals were collected, homogenized and filtered followed by protein extraction and profiling by quantitative label-free proteomics using Nano-Liquid Chromatography TripleTOF Mass Spectrometry. The mass spectra datasets were searched using MaxQuant against the fungi's Uniprot Fasta databases. Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 22. Fungal taxa associated with clinical parameters were identified using multivariate association with linear models.

Results We identified 570 fungal proteins secreted into the human gut. A distinct alteration in the diversity and composition of the fungal microbiota was observed in the CRC, with tremendous reductions of the overall fungal proteins, the diversity and composition of fungal microbiota as compared to the control ($p < 0.05$). Interestingly, the proportion of candida was increased in the CRC, indicating a modified gut microenvironment that favours the fungi. However, the discriminative distributions of the fungi secretome proteins in both CRC and non-CRC were observed with great individual variation.

Conclusions The distinct alteration of fungal proteins observed in CRC may suggest a possible CRC-specific gut microenvironment for fungi. This knowledge may be exploited for new therapeutic approaches for gut-related issues.

Basic Hepatology

IDDF2019-ABS-0174

TARGETING MONOCYTE-INTRINSIC ENHANCER REPROGRAMMING IMPROVES IMMUNOTHERAPY EFFICACY IN HEPATOCELLULAR CARCINOMA

¹Man Liu*, ²Jingying Zhou, ²Xiaoyu Liu, ²Yu Feng, ²Weiqin Yang, ³Feng Wu, ²Otto Ka-Wing Cheung, ⁴Hanyong Sun, ²Xuezhen Zeng, ²Wenshu Tang, ²Myth Tsz Shun Mok, ⁵John Wong, ⁵Philip Chun Yeung, ⁵Paul Bo San Lai, ⁶Zhiwei Chen, ⁷Hongchuan Jin, ⁸Jie Chen, ⁹Stephen Lam Chan, ³Anthony Wing-Hung Chan, ³Ka Fai To, ¹⁰Joseph Jao-Yiu Sung, ⁸Minhu Chen, ¹¹Alfred Sze-Lok Cheng. ¹School of Biomedical Sciences, The Chinese University of Hong Kong; ²Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China; ³School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong; ⁴Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong; ⁵Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; ⁶Department of Surgery, The Chinese University of Hong Kong, Hong Kong; ⁷AIDS Institute, Department of Microbiology and Research Center for Infection and Immunity, The University of Hong Kong, Hong Kong; ⁸Laboratory of Cancer Biology, Key Laboratory of Biotherapy in Zhejiang, Sir Runrun Shaw hospital, Medical School of Zhejiang University, Zhejiang, China; ⁹Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China; ¹⁰Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong; ¹¹Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong; ¹²School of Biomedical Sciences, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong

10.1136/gutjnl-2019-IDDFabstracts.4

Background Hepatocellular carcinoma (HCC), mostly developed in fibrotic/cirrhotic liver, exhibits relatively low responsiveness to immune-checkpoint blockade (ICB) therapy. As

Abstract IDDF2019-ABS-0174 Figure 1 BET and PD-L1 co-blockade synergistically enhanced TILs and eradicated HCC

myeloid-derived suppressor cell (MDSC) is pivotal for immunosuppression, we investigated its role and regulation in the fibrotic microenvironment with an aim of developing mechanism-based combination immunotherapy.

Methods Functional significance of MDSCs was evaluated by flow cytometry using two orthotopic HCC models in fibrotic liver setting via carbon tetrachloride or high-fat high-carbohydrate diet, and verified by clinical specimens. Mechanistic studies were conducted in the human hepatic stellate cell (HSC)-peripheral blood mononuclear cell culture systems and fibrotic-HCC patient-derived MDSCs. The efficacy of single or combined therapy with anti-programmed death-1-ligand-1 (anti-PD-L1) and a clinically-trialed BET bromodomain inhibitor i-BET762 was determined.

Results Accumulation of monocytic MDSCs (M-MDSCs), but not polymorphonuclear MDSCs, in fibrotic livers significantly correlated with reduced tumor-infiltrating lymphocytes (TILs) and increased tumorigenicity in both mouse models. In human HCCs, the tumor-surrounding fibrotic livers were markedly enriched with M-MDSC, with its surrogate marker CD33 significantly associated with aggressive tumor phenotypes and poor survival rates. Mechanistically, activated HSCs induced monocyte-intrinsic p38 MAPK signaling to trigger enhancer reprogramming for M-MDSC development and immunosuppression. Treatment with p38 MAPK inhibitor abrogated HSC-M-MDSC crosstalk to prevent HCC growth. Concomitant with patient-derived M-MDSC suppression by i-BET762, combined treatment with anti-PD-L1 synergistically enhanced TILs, resulting in tumor eradication and prolonged survival in the fibrotic-HCC mouse model.

Conclusions Our results signify how non-tumor intrinsic properties in the desmoplastic microenvironment can be exploited to reinstate immunosurveillance, providing readily translatable combination strategies to empower HCC immunotherapy (figure 1).

Acknowledgement This project is supported by the University Grants Committee through the Collaborative Research Fund (C4045-18W) and the Theme-based Research Scheme (T11-706/18-N), the Health and Medical Research Fund (16170451), the Terry Fox Foundation, the Focused Innovations Scheme-Scheme B (1907309) from the Chinese University of Hong Kong and the Li Ka Shing Foundation (Canada). Man Liu is supported by China Postdoctoral Science Foundation.

IDDF2019-ABS-0299

GUT MICROBIOME DIVERSITY AND SPECIFIC MICROBIAL GENERA CORRELATE WITH THE SEVERITY OF NON-ALCOHOLIC LIVER DISEASE IN INDONESIA

¹Chyntia Olivia Maurine Jasirwan*, ¹Cosmas Rinaldi Adhitya Lesmana, ¹Irsan Hasan, ²Marcellus Simadibrata, ³Ikhwana Rinaldi, ¹Juferdy Kurniawan, ¹Andri Sanityoso, ¹Saut Nababan, ¹Rino Alvani Gani. ¹Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; ²Gastroenterology Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; ³Clinical Epidemiology Unit and Hematology and Oncology Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia

10.1136/gutjnl-2019-IDDFabstracts.5

Background The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing. In Indonesia Hasan, I et al. (2002) reported the prevalence of 30.6%. This study evaluated the

first time the profile of gut microbiota and correlation with severity of NAFLD in Indonesia.

Methods We included 37 subjects age 18–60 years. The characteristic data of the patients and the food recalls were recorded. Abdominal ultrasound, liver transient elastography with controlled attenuation parameter (CAP) were performed. Next generation 16S rRNA metagenomic sequencing was conducted using stool samples. The Spearman correlation test was used to examine the correlation between specific microbial taxa with the severity of NAFLD based on fibrosis and steatosis degree.

Results The subjects included 62.2% (n=23) females and 37.8% males (n=14), mean age 50 ± 7.93 years old. They were divided based on fibrosis and steatosis degree into non-significant and significant fibrosis using cut off 7 KPa, mild and moderate-severe steatosis based on cut off 270 dB/m. From all subjects, we got 73% vs 27% non-significant and significant fibrosis, 51.4% vs 48.6% mild and moderate-severe steatosis. At the phylum level, the proportion of *Bacteroidetes* did not change in fibrosis or steatosis group. The proportion of *Proteobacteria* and *Firmicutes* was different in fibrosis and steatosis groups. *Actinobacteria unknown bifidobacteriales bifidobacteriaceae bifidobacterium Bifidobacterium adolescentis* correlate positively with non significant fibrosis ($r = 0.532$; $p=0.004$). *Firmicutes clostridia clostridiales lachnospiraceae unknown fusicatenibacter saccharivorans* and *Firmicutes clostridia clostridiales ruminococcaceae unknown [clostridium] leptum* correlate negatively with significant fibrosis ($r = -0.695$; $p=0.026$ vs $r = -0.732$; $p=0.016$). In the group of steatosis, we got *Bacteroidetes bacteroidia bacteroidales rikenellaceae alistipes alistipes onderdonkii* and *Firmicutes clostridia clostridiales oscillospiraceae oscillospiraceae scilibacter ruminantum* correlate negatively with moderate-severe steatosis ($r = -0.478$; $p=0.045$ vs $r = -0.518$; $p=0.028$); *Bacteroidetes bacteroidia bacteroidales rikenellaceae alistipes alistipes putredinis* correlate positively with mild steatosis ($r = 0.503$; $p=0.028$).

Conclusions The abundance of microbiota in NAFLD are not significantly different based on the group of fibrosis and steatosis, especially in phylum level. But at the lower level, some specific microbiota may correlate with the degree of fibrosis and steatosis.

Clinical Gastroenterology

IDDF2019-ABS-0042

PROSPECTIVE STUDY OF RISK SCORE STRATEGIES IN THE PREDICTION OF ADVANCED COLORECTAL NEOPLASIA AT COLONOSCOPY

¹Bianca So*, ²Yunki Yau, ²Viraj Kariyawasam, ³Rupert Leong. ¹Faculty of Medicine, University of New South Wales, Australia; ²Gastroenterology and Liver Services, Concord Repatriation General Hospital, Australia; ³Sydney Medical School, University of Sydney, Australia

10.1136/gutjnl-2019-IDDFabstracts.6

Background Current referral pathways in Australia for colorectal cancer (CRC) screening do not differentiate well between low and high-risk populations, and therefore may not be efficiently utilising resources. Whilst multiple CRC risk scoring systems currently exist and are utilised to stratify patients into low and high risk groups for priority of